BioSpace News Archive

AmerisourceBergen announced today that each company has independently determined that there is sufficient participation by states and litigating political subdivisions to proceed with a comprehensive agreement to settle the vast majority of the opioid lawsuits filed by state and local governmental entities.

Bristol Myers Squibb announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval of Opdivo for the adjuvant treatment of adults with muscle-invasive urothelial carcinoma with tumor cell PD-L1 expression ≥1% who are at a high risk of recurrence after undergoing radical resection.

Biohaven Pharmaceutical announced today that it entered into a worldwide license agreement with Bristol Myers Squibb (NYSE: BMY) for the development and commercialization rights to taldefgrobep alfa, a novel, Phase 3-ready anti-myostatin adnectin.

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Eisai today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved the combination of KEYTRUDA, Merck’s anti-PD-1 therapy, plus LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai, for radically unresectable or metastatic renal cell carcinoma (RCC).

CANbridge Pharmaceuticals, Inc. announced that CAN108, a treatment for Alagille syndrome, has been approved under the Early and Pilot Implementation Policy in Boao Lecheng International Medical Tourism Pilot Zone in China, which will allow it to be imported and used as an urgently needed drug in the zone.

Soft tissue retractors help enhance the view and illumination at a surgical site during various surgeries such as general surgery and minimally invasive procedures.

The global single lead ECG equipment market is likely to grow substantially in the coming years due to its increasing application in sports activities and monitoring heart rating during exercise.

Valneva SE, a specialty vaccine company, announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has provided an initial assessment of Valneva’s inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.

Cancer is defined as the abnormal growth of cells in the body. Cells located at any part of the body can turn cancerous and spread to other parts of the body.

The human immune system is a constant sentinel that seeks out unwelcome invaders in the body such as viruses, bacteria, as well as some elements that might be an indication of disease or dysfunction.